Security Snapshot

BridgeBio Oncology Therapeutics, Inc. - Common Stock (BBOT) Institutional Ownership

CUSIP: 107924102

13F Institutional Holders and Ownership History from Q3 2025 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

67

Shares (Excl. Options)

52.16MFull value: 52,156,214 · shares · 30 Sep 2026

Price

$4.10

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
-3,420,038
Value change
-$16,997,278
Number of holders
67
Issuer context Names, identifiers, and filing context for this profile. 2 identity fields
Shares outstanding
80,260,026
SEC-reported price per share
$2.70
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • BBOT - BridgeBio Oncology Therapeutics, Inc. - Common Stock is tracked under CUSIP 107924102.
  • 67 institutions reported positions in Q3 2026.
  • 8 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 65 to 67 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $450.58MFull value: $450,584,191 · USD · 30 Jun 2026
    to
    $213.79MFull value: $213,793,942 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 67 institutions filings for Q3 2026.

Open SEC evidence

Security key

107924102

13F reference period

Q3 2026

13F holders

67

13D/G owners

8

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
8
Security
BBOT
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Helix Holdings II LLC 23% 17,878,594 Bihua Chen 11 Aug 2025
Chen Bihua 22% $139,095,461 17,878,594 Bihua Chen 01 Jul 2026
BridgeBio Pharma LLC 18% 13,878,554 BridgeBio Pharma LLC 11 Aug 2025
BC Global Opportunities IX LP 5.5% $42,740,663 4,365,747 BC Global Opportunities IX LP 04 Sep 2025
Flynn James E 3.9% -38% $12,364,378 -$6,884,279 3,138,167 -36% Deerfield Management Company, L.P. 30 Sep 2026
CITADEL ADVISORS LLC 3.2% $29,391,684 2,538,142 Kenneth Griffin 30 Sep 2025
Adage Capital Management, L.P. 1.9% $17,226,651 1,487,621 Adage Capital Management, L.P. 30 Sep 2025
PRICE T ROWE ASSOCIATES INC /MD/ 1.1% $10,248,786 885,042 T. Rowe Price Associates, Inc. 30 Sep 2025
As of 30 Sep 2026, 67 institutional investors reported holding
52.16MFull value: 52,156,214 · shares · 30 Sep 2026
shares of BridgeBio Oncology Therapeutics, Inc. - Common Stock (BBOT). This represents 65% of the company’s total
80.26MFull value: 80,260,026 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
62%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Cormorant Asset Management, LP 22% 17,878,594 4.9% $73,302,235
Omega Fund Management, LLC 4.1% 3,289,661 11% $13,487,610
DEERFIELD MANAGEMENT COMPANY, L.P. 3.9% 3,138,167 0.2% $12,866,485
Alphabet Inc. 3.5% 2,823,126 0.01% $11,574,817
ENAVATE SCIENCES GP, LLC 3.3% 2,626,946 3.8% $10,770,479
REGENTS OF THE UNIVERSITY OF CALIFORNIA 3.1% 2,509,446 0.15% $10,288,729
ARMISTICE CAPITAL, LLC 2.8% 2,264,000 0.31% $9,282,400
NOVO HOLDINGS A/S 2.8% 2,250,000 0.62% $9,225,000
Laurion Capital Management LP 2.5% 2,002,701 0.62% $8,211,074
VANGUARD CAPITAL MANAGEMENT LLC 2.5% 1,991,016 0% $8,163,166
WELLINGTON MANAGEMENT GROUP LLP 1.8% 1,430,687 0% $5,865,817
Aisling Capital Management LP 1.3% 1,018,018 1.4% $4,137,874
STATE STREET CORP 1.1% 893,262 0% $3,662,374
EcoR1 Capital, LLC 1.1% 889,607 0.18% $3,647,389
Catalio Capital Management, LP 0.87% 699,532 0.53% $2,868,081
Opaleye Management Inc. 0.78% 630,000 0.29% $2,583,000
GEODE CAPITAL MANAGEMENT, LLC 0.69% 556,989 0% $2,284,925
MARSHALL WACE, LLP 0.6% 482,935 0% $1,980,035
SPHERA FUNDS MANAGEMENT LTD. 0.58% 464,480 0.29% $1,904,368
Granahan Investment Management, LLC 0.54% 437,004 0.08% $1,791,716
ADAGE CAPITAL PARTNERS GP, L.L.C. 0.5% 400,000 0% $1,640,000
Qube Research & Technologies Ltd 0.36% 290,548 0% $1,191,247
Casdin Capital, LLC 0.35% 282,312 0.05% $1,157,479
DAFNA Capital Management LLC 0.33% 266,038 0.23% $1,090,756
VANGUARD FIDUCIARY TRUST CO 0.33% 264,427 0% $1,084,151

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
5
Headline period
Q3 2026
Rows shown
1-5 of 5
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 52,156,214 $213,793,942 -$16,997,278 $4.10 67
2026 Q2 59,128,415 $450,584,191 +$8,267,743 $7.62 65
2026 Q1 57,435,188 $513,833,746 -$6,100,446 $8.95 67
2025 Q4 57,897,060 $724,704,890 +$13,675,814 $12.52 52
2025 Q3 56,812,363 $657,547,712 +$657,547,712 $11.58 41
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .